GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » VolitionRX Ltd (AMEX:VNRX) » Definitions » Financial Strength

VolitionRX (VolitionRX) Financial Strength : 2 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is VolitionRX Financial Strength?

VolitionRX has the Financial Strength Rank of 2. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.

Warning Sign:

VolitionRX Ltd displays poor financial strength. Usually, this is caused by too much debt for the company.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

VolitionRX did not have earnings to cover the interest expense. VolitionRX's debt to revenue ratio for the quarter that ended in Dec. 2023 was 6.00. As of today, VolitionRX's Altman Z-Score is -13.66.


Competitive Comparison of VolitionRX's Financial Strength

For the Diagnostics & Research subindustry, VolitionRX's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VolitionRX's Financial Strength Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, VolitionRX's Financial Strength distribution charts can be found below:

* The bar in red indicates where VolitionRX's Financial Strength falls into.



VolitionRX Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

VolitionRX's Interest Expense for the months ended in Dec. 2023 was $-0.06 Mil. Its Operating Income for the months ended in Dec. 2023 was $-8.74 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $4.40 Mil.

VolitionRX's Interest Coverage for the quarter that ended in Dec. 2023 is

VolitionRX did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

VolitionRX's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2023 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.455 + 4.403) / 0.976
=6.00

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

VolitionRX has a Z-score of -13.66, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -13.66 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


VolitionRX  (AMEX:VNRX) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

VolitionRX has the Financial Strength Rank of 2. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.


VolitionRX Financial Strength Related Terms

Thank you for viewing the detailed overview of VolitionRX's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


VolitionRX (VolitionRX) Business Description

Traded in Other Exchanges
N/A
Address
1489 West Warm Springs Road, Suite 110, Henderson, NV, USA, 89014
VolitionRX Ltd is a United states based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
Executives
Eight Corp Ltd 10 percent owner C/O CROWE MORGAN, 8 ST. GEORGE'S STREET, DOUGLAS Y8 IM1 1AH
Salvatore Thomas Butera director 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Rodney Gerard Rootsaert director, officer: SECRETARY 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Cameron John Reynolds director, officer: PRESIDENT AND CEO 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Guy Archibald Innes director 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Edward Futcher director 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Phillip Barnes director 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Martin Charles Faulkes director 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Mickie Henshall director 1489 WEST WARM SPRINGS ROAD,, SUITE 110, HENDERSON NV 89014
Jacob Vincent Micallef officer: Chief Scientific Officer 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Michel Gaetan other: Manager Belgian Volition SPRL 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Jasmine Kway other: CEO-Singapore Volition 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Nicholas Plummer officer: GC - Volition Diagnostics 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Ann-louise Batchelor officer: Group Chief Marketing Officer 1489 WEST WARM SPRINGS ROAD,, SUITE 110, HENDERSON NV 89014
Terrell Jason Bradley Md officer: Chief Medical Officer 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014